Interferon therapy for aged patients with chronic hepatitis C: Improved survival in patients exhibiting a biochemical response

Journal of Gastroenterology

Volumn 39, Issue 11, 2004, Pages 1069-1077

  Imai, Yasuharu ^a   Kasahara, Akinori ^b   Tanaka, Hideo ^c   Okanoue, Takeshi ^d   Hiramatsu, Naoki ^b   Tsubouchi, Hirohito ^e   Yoshioka, Kentaro ^f   Kawata, Sumio ^g   Tanaka, Eiji ^h   Hino, Keisuke ⁱ   Hayashi, Katsuhiro ^e   Tamura, Shinji ^b   Itoh, Yoshito ^b   Sasaki, Yutaka ^j   Kiyosawa, Kendo ^h   Kakumu, Shinichi ^k   Okita, Kiwamu ⁱ   Hayashi, Norio ^d  

^a IKEDA MUNICIPAL HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e UNIVERSITY OF MIYAZAKI   (Japan)

^f NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g YAMAGATA UNIVERSITY   (Japan)

^h SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j KUMAMOTO UNIVERSITY   (Japan)

^k AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Aged; Chronic hepatitis C; Interferon; Liver related mortality; Standardized mortality ratio

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CAUSE OF DEATH; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG RESPONSE; FOLLOW UP; GERIATRIC PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MORTALITY; NONBIOLOGICAL MODEL; NONHUMAN; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; SURVIVAL;

AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOPSY; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 10244245503     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-004-1448-0     Document Type: Article

References (34)

1. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Semin Liver Dis 1995;15:64-9.
2. Nishioka K, Watanabe J, Furuta S, Tanaka E, Iino S, Suzuki H, et al. A prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 1991;67:429-33.
3. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797-801.
4. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
5. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27:1394-402.
6. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 1998;129:94-9.
7. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131:174-81.
8. Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage; a retrospective study of 1146 patients. J Hepatol 1999;30:653-9.
9. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124-30.
10. Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: A retrospective cohort study of 738 patients. Int J Cancer 2000;87:741-9.
11. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998;83:901-9.
12. Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, et al. Treatment of hepatitis C virus-related cirrhosis: A randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999;29:1870-5.
13. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27:1435-40.
14. Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001;357:196-7.
15. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
16. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Prognosis of chronic hepatitis C: Results of a large prospective cohort study. Hepatology 1998;28:1687-95.
17. Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002;123:483-91.
18. Okanoue T, Itoh Y, Kirishima T, Daimon Y, Toyama T, Morita A, et al. Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma and improves the long-term survival of chronic hepatitis C patients. Hepatology Res 2002;23:62-77.
19. Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 2003;38:493-502.
20. Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat 2004;11:148-56.
21. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized controlled trial. N Engl J Med 1989;321:1501-6.
22. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double blind placebo-controlled trial. N Engl J Med 1989;321:1506-10.
23. Hagiwara H, Hayashi N, Mita E, Hiramatsu N, Ueda K, Takehara T, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993;104:877-83.
24. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial. Hepatology 1995;21:291-7.
25. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 1997;113: 558-66.
26. McHutchison JG, Gordon SC, Schiff ER, Schiffman ML, Lee WM, Rustgi VK, et al. Interferon alpha 2b alone or combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
27. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomized trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
28. Fried MW, Schiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
29. Tanaka H, Tsukuma H. Hepatitis C virus. In: J Tooze, editor. Cancer survey, vol. 33. New York: Cold Spring Harbor Laboratory Press; 1999. p. 213-35.
30. Yoshizawa H. Trends of hepatitis virus carriers. Hepatology Res 2002;24:S28-39.
31. Tanaka H, Tsukuma H. Characteristics of Japanese patients with liver cancer - epidemiological study based on a comparison between male and female patients. Hepatology Res 2002;24:S11-20.
32. Okanoue T, Yasui K, Sakamoto S, Minami M, Nagao Y, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-91.
33. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Sheuer PJ. Classification of chronic hepatitis: Grading and staging. Hepatology 1994;19:1513-20.
34. Statistics and Information Department, Japan Ministry of Health and Welfare. Vital statistics in Japan (in Japanese). Tokyo: Health and Welfare Statistics Association; 2002.